scispace - formally typeset
N

Neil J. Todd

Researcher at St James's University Hospital

Publications -  11
Citations -  624

Neil J. Todd is an academic researcher from St James's University Hospital. The author has contributed to research in topics: Stenotrophomonas maltophilia & Plasmid. The author has an hindex of 11, co-authored 11 publications receiving 602 citations.

Papers
More filters
Journal ArticleDOI

Molecular Epidemiology of Stenotrophomonas maltophilia Isolated from Clinical Specimens from Patients with Cystic Fibrosis and Associated Environmental Samples

TL;DR: There was some evidence that a small number of patients may have acquired the organism from the hospital environment, and the source of the majority of S. maltophiliastrains colonizing the respiratory tracts of these patients with cystic fibrosis remained uncertain.
Journal ArticleDOI

Transcontinental importation into the UK of Escherichia coli expressing a plasmid-mediated AmpC-type beta-lactamase exposed during an outbreak of SHV-5 extended-spectrum beta-lactamase in a Leeds hospital.

TL;DR: The ease with which highly resistant bacteria can be imported into the UK and spread within hospitals is demonstrated, particularly amongst patients on the liver transplant unit.
Journal ArticleDOI

Role of anti-pseudomonal antibiotics in the emergence of Stenotrophomonas maltophilia in cystic fibrosis patients

TL;DR: In the year prior to initial isolation, colonised patients spent more days in hospital and received more days of oral ciprofloxacin, intravenous anti-pseudomonal antibiotics, and nebulised aminoglycosides.
Journal ArticleDOI

Molecular epidemiology of ceftazidime resistant Enterobacteriaceae from patients on a paediatric oncology ward

TL;DR: Strains isolated in this study showed multiple resistance to a range of antimicrobial agents and ribotype patterns derived from the clinical isolates provided evidence for cross-colonisation between patients, and this was confirmed by analysis of the plasmid profiles.
Journal ArticleDOI

CTX-M extended-spectrum β-lactamase arrives in the UK

TL;DR: It is a concern that diagnostic laboratories will fail to recognize CTX-M-positive strains as ESBL producers, as it is common practice to screen for ceftazidime resistance as an indicator of ESBLs, on the grounds that it tends to be the best indicator substrate for TEM and SHV variants.